Miquel Martínez-Navarrete , Mafalda Correia , J.Alejandro Bernabeu-Martínez , Ana Cláudia Paiva-Santos , Ana Borrego-Sánchez , Antonio José Guillot
{"title":"Enhanced ex vivo skin retention of bicalutamide using a nano-in-micro composite: Drug-loaded lipid vesicles in a dissolving microarray patch","authors":"Miquel Martínez-Navarrete , Mafalda Correia , J.Alejandro Bernabeu-Martínez , Ana Cláudia Paiva-Santos , Ana Borrego-Sánchez , Antonio José Guillot","doi":"10.1016/j.ejpb.2025.114728","DOIUrl":null,"url":null,"abstract":"<div><div>Antiandrogens are a family of drugs that block the biological effects of androgens, which are commonly used to treat a plethora of androgen-dependent conditions. However, their effectiveness highly depends on treatment compliance and their use is not exempt from side effects. Bicalutamide (BIC) is a testosterone blocker that, due to its peripheral tissue selectivity, offers the advantage of fewer side effects compared to other antiandrogens such as finasteride or dutasteride. In this study, BIC-loaded lipid vesicles (LVs) were developed and incorporated into a PVP/PVA-based Dissolving Microarray Patches (BIC-LVs@DMAPs) for BIC skin local delivery. First, the mechanical and insertion properties of the BIC-LVs@DMAPs were assessed. Then, the <em>in vitro</em> biocompatibility of the formulation was determined in keratinocytes. Finally, the effectiveness of the formulation to deliver BIC through skin was explored <em>ex vivo</em> using murine skin. BIC-LVs@DMAPs exhibited optimal mechanical and insertion properties to effectively perforate the <em>stratum corneum</em> and facilitate the passage of BIC-LVs. <em>Ex vivo</em> studies demonstrated the efficacy of BIC-LVs@DMAPs to improve the skin retention of BIC, while <em>in vitro</em> cytotoxicity results ensured their safety profile. Overall, these results pave the way for further <em>in vivo</em> studies and clinical application to improve the current early stages androgenetic alopecia topical treatments.</div></div>","PeriodicalId":12024,"journal":{"name":"European Journal of Pharmaceutics and Biopharmaceutics","volume":"212 ","pages":"Article 114728"},"PeriodicalIF":4.4000,"publicationDate":"2025-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Pharmaceutics and Biopharmaceutics","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0939641125001055","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Antiandrogens are a family of drugs that block the biological effects of androgens, which are commonly used to treat a plethora of androgen-dependent conditions. However, their effectiveness highly depends on treatment compliance and their use is not exempt from side effects. Bicalutamide (BIC) is a testosterone blocker that, due to its peripheral tissue selectivity, offers the advantage of fewer side effects compared to other antiandrogens such as finasteride or dutasteride. In this study, BIC-loaded lipid vesicles (LVs) were developed and incorporated into a PVP/PVA-based Dissolving Microarray Patches (BIC-LVs@DMAPs) for BIC skin local delivery. First, the mechanical and insertion properties of the BIC-LVs@DMAPs were assessed. Then, the in vitro biocompatibility of the formulation was determined in keratinocytes. Finally, the effectiveness of the formulation to deliver BIC through skin was explored ex vivo using murine skin. BIC-LVs@DMAPs exhibited optimal mechanical and insertion properties to effectively perforate the stratum corneum and facilitate the passage of BIC-LVs. Ex vivo studies demonstrated the efficacy of BIC-LVs@DMAPs to improve the skin retention of BIC, while in vitro cytotoxicity results ensured their safety profile. Overall, these results pave the way for further in vivo studies and clinical application to improve the current early stages androgenetic alopecia topical treatments.
期刊介绍:
The European Journal of Pharmaceutics and Biopharmaceutics provides a medium for the publication of novel, innovative and hypothesis-driven research from the areas of Pharmaceutics and Biopharmaceutics.
Topics covered include for example:
Design and development of drug delivery systems for pharmaceuticals and biopharmaceuticals (small molecules, proteins, nucleic acids)
Aspects of manufacturing process design
Biomedical aspects of drug product design
Strategies and formulations for controlled drug transport across biological barriers
Physicochemical aspects of drug product development
Novel excipients for drug product design
Drug delivery and controlled release systems for systemic and local applications
Nanomaterials for therapeutic and diagnostic purposes
Advanced therapy medicinal products
Medical devices supporting a distinct pharmacological effect.